U.S. markets closed
  • S&P 500

    4,163.29
    -10.56 (-0.25%)
     
  • Dow 30

    34,327.79
    -54.34 (-0.16%)
     
  • Nasdaq

    13,379.05
    -50.93 (-0.38%)
     
  • Russell 2000

    2,227.12
    +2.49 (+0.11%)
     
  • Crude Oil

    66.29
    +0.02 (+0.03%)
     
  • Gold

    1,867.20
    -0.40 (-0.02%)
     
  • Silver

    28.31
    +0.03 (+0.11%)
     
  • EUR/USD

    1.2157
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • GBP/USD

    1.4139
    +0.0037 (+0.26%)
     
  • USD/JPY

    109.2030
    -0.1440 (-0.13%)
     
  • BTC-USD

    43,207.64
    -2,486.23 (-5.44%)
     
  • CMC Crypto 200

    1,195.01
    -2.91 (-0.24%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Horizon Pharma files patent infringement lawsuit against Watson Laboratories

Horizon Pharma announced it, along with SkyePharma from whom it has licensed certain RAYOS intellectual property, has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Watson Laboratories Florida and certain related companies, or WLF and related to an Abbreviated New Drug Application, or ANDA, that WLF filed with the FDA to market generic versions of RAYOS containing 1 mg, 2 mg and 5 mg of prednisone. WLF alleged that its generic versions of RAYOS would not infringe the subject U.S. patents or the patents are invalid or unenforceable. WLF has not advised Horizon as to the timing or status of the FDA's review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. The defendants in the lawsuit are Watson Laboratories- Florida, Actavis Pharma, Andrx and Actavis.